Malignant Lymphomas

For over 20 years, the International Conference on Malignant Lymphoma (ICML) has established itself as a leading global event in the field of malignant lymphomas. Its origins, however, were quite serendipitous.

In the 1970s and 1980s the introduction of combination chemotherapy regimens greatly improved the cure rates for patients with Hodgkin’s disease. One of these first regimens was the ABVD combination (adriamycin, bleomycin, vinblastine and dacarbazine).